Literature DB >> 19748274

Tetraiodobenzimidazoles are potent inhibitors of protein kinase CK2.

Alessandra Gianoncelli1, Giorgio Cozza, Andrzej Orzeszko, Flavio Meggio, Zygmunt Kazimierczuk, Lorenzo A Pinna.   

Abstract

A series of novel iodinated benzimidazoles have been prepared by iodination of respective benzimidazole with iodine and periodic acid in sulfuric acid solution. Additionally several 2-substituted- and N-1-carboxymethyl-substituted derivatives of 4,5,6,7-tetraiodobenzimidazole (TIBI) were obtained. For sake of comparison, some new 4,5,6,7-tetrabromobenzimidazoles were also synthesized. The ability of the new compounds to inhibit protein kinase CK2 has been evaluated. The results show that 4,5,6,7-tetraiodobenzimidazoles are more powerful inhibitors of CK2 than their tetrabrominated analogs. Molecular modeling supports the experimental data showing that tetraiodobenzimidazole moiety fills better the binding pocket than respective tetrabromo and tetrachlorocompounds. To note that 4,5,6,7-tetraiodobenzimidazole (TIBI) is one of the most efficient CK2 inhibitors (K(i)=23 nM) described to date.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19748274     DOI: 10.1016/j.bmc.2009.08.047

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  9 in total

1.  Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.

Authors:  Janeen H Trembley; Gretchen M Unger; Omar Cespedes Gomez; J Abedin; Vicci L Korman; Rachel I Vogel; Gloria Niehans; Betsy T Kren; Khalil Ahmed
Journal:  Mol Cell Pharmacol       Date:  2014

2.  Unbiased functional proteomics strategy for protein kinase inhibitor validation and identification of bona fide protein kinase substrates: application to identification of EEF1D as a substrate for CK2.

Authors:  Laszlo Gyenis; James S Duncan; Jacob P Turowec; Maria Bretner; David W Litchfield
Journal:  J Proteome Res       Date:  2011-10-13       Impact factor: 4.466

Review 3.  The Development of CK2 Inhibitors: From Traditional Pharmacology to in Silico Rational Drug Design.

Authors:  Giorgio Cozza
Journal:  Pharmaceuticals (Basel)       Date:  2017-02-20

Review 4.  The Link between Protein Kinase CK2 and Atypical Kinase Rio1.

Authors:  Konrad Kubiński; Maciej Masłyk
Journal:  Pharmaceuticals (Basel)       Date:  2017-02-07

5.  Benzimidazole inhibitors of protein kinase CK2 potently inhibit the activity of atypical protein kinase Rio1.

Authors:  Konrad Kubiński; Maciej Masłyk; Andrzej Orzeszko
Journal:  Mol Cell Biochem       Date:  2016-12-01       Impact factor: 3.396

Review 6.  Looking Back, Looking Forward at Halogen Bonding in Drug Discovery.

Authors:  Lois Mendez; Gabriela Henriquez; Suman Sirimulla; Mahesh Narayan
Journal:  Molecules       Date:  2017-08-24       Impact factor: 4.411

7.  Antitumor activity of the protein kinase inhibitor 1-(β-D-2'-deoxyribofuranosyl)-4,5,6,7-tetrabromo- 1H-benzimidazole in breast cancer cell lines.

Authors:  Mirosława Koronkiewicz; Zygmunt Kazimierczuk; Andrzej Orzeszko
Journal:  BMC Cancer       Date:  2022-10-15       Impact factor: 4.638

8.  Synthesis of Novel Halogenated Heterocycles Based on o-Phenylenediamine and Their Interactions with the Catalytic Subunit of Protein Kinase CK2.

Authors:  Maria Winiewska-Szajewska; Agnieszka Monika Maciejewska; Elżbieta Speina; Jarosław Poznański; Daniel Paprocki
Journal:  Molecules       Date:  2021-05-25       Impact factor: 4.411

9.  Proapoptotic effects of novel pentabromobenzylisothioureas in human leukemia cell lines.

Authors:  Mirosława Koronkiewicz; Zdzisław Chilmonczyk; Zygmunt Kazimierczuk
Journal:  Med Chem Res       Date:  2011-11-11       Impact factor: 1.965

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.